American Society of Hematology

ASH Summit on Emerging Immunotherapies for Hematologic Diseases

July 12-13, 2018
Omni Shoreham Hotel, Washington, DC

Visit ASH Academy to complete the post-meeting evaluation, claim CME/MOC, or request a certificate of attendance.

The ASH Summit on Emerging Immunotherapies for Hematologic Diseases examined preclinical and clinical factors influencing the effective development, regulation, and implementation of immunotherapies for hematologic diseases. The summit’s interactive format included didactic and breakout sessions, panel discussions, and opportunities to foster strategic collaborations among stakeholder groups focused on immunotherapy research and clinical translation. View the 2018 program.

Through participation in this meeting, attendees were able to:

  • Learn about the state of immunotherapy and its application to hematologic diseases.
  • Gain insight on the use of combination therapies in the treatment of hematologic diseases.
  • Learn about regulation and implementation of immunotherapies into clinical practice.
  • Review strategies to diagnose, mitigate, and treat toxicities resulting from the use of these therapies.
  • Develop a better understanding of the use of cell-based therapies for the treatment on non-malignant and virus-associated hematologic diseases.
  • Discuss scientific, clinical, and regulatory aspects critical for the design of later-phase immunotherapy clinical trials.
  • Network and set up collaborations with experts, regulatory scientists, industry, and other stakeholders.
  • Earn CME and MOC credits.

Target Audience

  • Laboratory-based investigators
  • Translational and clinical researchers
  • Policymakers and regulatory scientists
  • Clinicians, physicians, and other health professionals interested in immunotherapies
  • Cellular therapy, gene therapy, biopharmaceutical, and life sciences industry
  • Clinical trialists
  • Patient advocacy groups
  • Payers and health care providers

Program Co-Chairs

  • Catherine Bollard, MD, Children’s National Health System
  • Rodrigo Calado, MD, PhD, University of São Paulo
  • Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center
  • Jeffrey Miller, MD, University of Minnesota

ASH Task Force on Immunotherapies

  • Sophie Paczesny, MD, Indiana University School of Medicine, Task Force Co-Chair
  • Steven Pavletic, MD, National Cancer Institute, National Institutes of Health, Task Force Co-Chair
  • Joseph Alvarnas, MD, City of Hope National Medical Center
  • Catherine Bollard, MD, Children’s National Health System
  • Rodrigo Calado, MD, PhD, University of São Paulo, Brazil
  • Colleen Delaney, MD, MSc, Fred Hutchinson Cancer Research Center
  • Mary Dinauer, MD, PhD, Washington University in St. Louis
  • Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center
  • Jennifer Holter-Chakrabarty, MD, University of Oklahoma
  • James Kochenderfer, MD, National Cancer Institute, National Institutes of Health
  • Jeffrey S. Miller, MD, University of Minnesota

Exposition

The 2018 ASH Summit on Emerging Immunotherapies for Hematologic Diseases meeting featured an exhibition of products and services in the areas of hematology and blood transfusion. Participants in this exposition are comprised of the most renowned companies in the industry, including:

  • BMS/Pfizer
  • Beckman Coulter Life Sciences
  • Atara Biotherapeutics
  • Novartis Oncology

For information about sponsoring and/or exhibiting at SEIHD, contact Thelma Barnett at corporatesupport@hematology.org.

Corporate Support

ASH would like to acknowledge the following companies for the educational grants provided in support of the ASH Summit on Emerging Immunotherapies for Hematologic Diseases.

  • Celgene Corporation
  • Incyte Corporation
  • Kite Pharma, A Gilead Company
  • Merck & Co.
  • Novartis Pharmaceuticals, Inc.
  • Pharmacyclics, An AbbVie Company

Questions?

Please submit all general inquiries about this meeting to ashsummit@hematology.org.

back to top